Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Short Interest Update

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 145,548 shares, a decline of 34.7% from the July 30th total of 222,920 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 69,205 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analyst Weigh In

Separately, BTIG Research started coverage on Serina Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Serina Therapeutics has a consensus rating of “Buy” and an average target price of $8.00.

Serina Therapeutics Stock Up 3.3%

Shares of SER stock traded up $0.08 during trading on Tuesday, hitting $2.50. 32,395 shares of the company were exchanged, compared to its average volume of 1,740,999. The business’s 50-day simple moving average is $2.25 and its 200 day simple moving average is $2.01. Serina Therapeutics has a twelve month low of $1.22 and a twelve month high of $5.83. The firm has a market capitalization of $63.50 million, a price-to-earnings ratio of -1.32 and a beta of 1.11. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.